deepalisinghal

Deep research is central to Perpetuity’s investment culture. Each year, we let the numbers reveal how the listed healthcare sector is evolving. This blog continues our annual analysis of the sector’s financial performance and the structural shifts shaping its growth. Healthcare Sector Performance Across Decades: Healthcare, often considered a 'defensive sector', has delivered returns consistent with that perception. Except over the 10-year horizon, which begins at the cyclical peak of US...

In our previous blog, “GLP-1: From Diabetes Niche to Obesity Blockbuster – The Next Pharma Supercycle”, we discussed how GLP-1 therapies were reshaping diabetes and obesity treatment. Since then, annualized GLP-1 sales have scaled to ~US$89 billion by Q1CY26, reinforcing the magnitude of the opportunity. However, a new phase is now emerging. Semaglutide — the molecule behind Ozempic and Wegovy — has begun losing exclusivity across several emerging markets during 2026. This shift from an...